SEC Comment Letter for INTROGEN THERAPEUTICS INC (CIK 0001018710) — Oct 24, 2005
INTROGEN THERAPEUTICS INC (CIK 0001018710)
Date: Oct. 24, 2005 · CIK: 0001018710 · Accession: 0000000000-05-054043
AI Filing Summary & Sentiment
File numbers found in text: 000-21291
Letter
Via Facsimile and U.S. Mail Mail Stop 6010 October 24, 2005 Mr. James W. Albrecht, Jr. Chief Financial Officer Introgen Therapeutics, Inc. 301 Congress Avenue, Suite 1850 Austin, TX 78701
Re: Introgen Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2004 Form 10-Q for the quarter ended March 31, 2005 File No. 000-21291
Dear Mr. Albrecht:
We have completed our review of your Form 10-K and related filings and have no further comments at this time.
Sincerely,
Joel Parker
Accounting Branch Chief
Show Raw Text
<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
Via Facsimile and U.S. Mail
Mail Stop 6010
October 24, 2005
Mr. James W. Albrecht, Jr.
Chief Financial Officer
Introgen Therapeutics, Inc.
301 Congress Avenue, Suite 1850
Austin, TX 78701
Re: Introgen Therapeutics, Inc.
Form 10-K for the fiscal year ended December 31, 2004
Form 10-Q for the quarter ended March 31, 2005
File No. 000-21291
Dear Mr. Albrecht:
We have completed our review of your Form 10-K and related
filings and have no further comments at this time.
Sincerely,
Joel Parker
Accounting Branch Chief
</TEXT>
</DOCUMENT>